Trial · NCT01704261
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Omarigliptin | 4 | 153 | 4 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 9 | 153 | 11 |
| other | Urinary tract infection | Infections and infestations | Omarigliptin | 9 | 153 | 9 |
| other | Urinary tract infection | Infections and infestations | Placebo | 3 | 153 | 4 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Omarigliptin | 18 | 153 | 65 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Placebo | 13 | 153 | 44 |
| serious | Vertigo | Ear and labyrinth disorders | Omarigliptin | 1 | 153 | 1 |
| serious | Vertigo | Ear and labyrinth disorders | Placebo | 0 | 153 | 0 |
| serious | Duodenal ulcer haemorrhage | Gastrointestinal disorders | Omarigliptin | 0 | 153 | 0 |
| serious | Duodenal ulcer haemorrhage | Gastrointestinal disorders | Placebo | 1 | 153 | 1 |
| serious | Oesophagitis | Gastrointestinal disorders | Omarigliptin | 0 | 153 | 0 |
| serious | Oesophagitis | Gastrointestinal disorders | Placebo | 1 | 153 | 1 |
| serious | Pancreatitis | Gastrointestinal disorders | Omarigliptin | 0 | 153 | 0 |
| serious | Pancreatitis | Gastrointestinal disorders | Placebo | 1 | 153 | 1 |
| serious | Non-cardiac chest pain | General disorders | Omarigliptin | 1 | 153 | 1 |
| serious | Non-cardiac chest pain | General disorders | Placebo | 0 | 153 | 0 |
| serious | Cholecystitis | Hepatobiliary disorders | Omarigliptin | 1 | 153 | 1 |
| serious | Cholecystitis | Hepatobiliary disorders | Placebo | 0 | 153 | 0 |
| serious | Road traffic accident | Injury, poisoning and procedural complications | Omarigliptin | 0 | 153 | 0 |
| serious | Road traffic accident | Injury, poisoning and procedural complications | Placebo | 1 | 153 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01704261/events